Min Ji Jeon1, Sung Min Chun2,3, Ji-Young Lee3, Kyeong Woon Choi4, Deokhoon Kim3, Tae Yong Kim1, Se Jin Jang2, Won Bae Kim1, Young Kee Shong1, Dong Eun Song5, Won Gu Kim6. 1. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. 2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. 3. Center for Cancer Genome Discovery, Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. 4. Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. 5. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. desong@amc.seoul.kr. 6. Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 05505, Korea. wongukim@amc.seoul.kr.
Abstract
PURPOSE: Papillary thyroid microcarcinoma (PTMC) has excellent outcomes, but extensive lymph node (LN) metastasis can be associated with fatal outcomes. We evaluated the mutational profiles of primary tumors and their metastatic LNs of PTMCs with extensive lateral cervical LN metastases. METHODS: Formalin-fixed, paraffin-embedded archival samples from 16 sets of normal thyroid tissue, the primary PTMC, and the largest metastatic LN were used for targeted sequencing. RESULTS: A total of seven somatic variants were confirmed in the PTMCs compared to the normal tissue. The BRAFV600E mutation was the most common and seen in 12 primary tumors (75%) and 11 metastatic LNs (69%). A nonsense mutation in AR and an in-frame deletion in ACVR2A were detected in one primary tumor and its metastatic LN (6%). Missense mutations in KMT2A, RAF1, and ROS1 were detected in one primary tumor (3%). A frameshift deletion mutation in JAK2 was detected in a metastatic LN (3%). In PTMCs without the BRAF mutation, an ALK and RET rearrangement (one PTMC and its metastatic LN, 6%) was detected. In one patient, the BRAF mutation was detected in the primary tumor, but only a RET rearrangement was detected in its metastatic LN. No mutations were detected in two patients. CONCLUSION: The mutational frequency of PTMCs was really low, even in those with extensive LN metastasis. The mutational status of the primary tumor and its metastatic LNs were not significantly different, and this suggests a minor role for genetic alterations in the process of LN metastasis in PTMC.
PURPOSE:Papillary thyroid microcarcinoma (PTMC) has excellent outcomes, but extensive lymph node (LN) metastasis can be associated with fatal outcomes. We evaluated the mutational profiles of primary tumors and their metastatic LNs of PTMCs with extensive lateral cervical LN metastases. METHODS:Formalin-fixed, paraffin-embedded archival samples from 16 sets of normal thyroid tissue, the primary PTMC, and the largest metastatic LN were used for targeted sequencing. RESULTS: A total of seven somatic variants were confirmed in the PTMCs compared to the normal tissue. The BRAFV600E mutation was the most common and seen in 12 primary tumors (75%) and 11 metastatic LNs (69%). A nonsense mutation in AR and an in-frame deletion in ACVR2A were detected in one primary tumor and its metastatic LN (6%). Missense mutations in KMT2A, RAF1, and ROS1 were detected in one primary tumor (3%). A frameshift deletion mutation in JAK2 was detected in a metastatic LN (3%). In PTMCs without the BRAF mutation, an ALK and RET rearrangement (one PTMC and its metastatic LN, 6%) was detected. In one patient, the BRAF mutation was detected in the primary tumor, but only a RET rearrangement was detected in its metastatic LN. No mutations were detected in two patients. CONCLUSION: The mutational frequency of PTMCs was really low, even in those with extensive LN metastasis. The mutational status of the primary tumor and its metastatic LNs were not significantly different, and this suggests a minor role for genetic alterations in the process of LN metastasis in PTMC.
Entities:
Keywords:
DNA mutational analysis; High-throughput nucleotide sequencing; Papillary thyroid microcarcinoma; Translational research
Authors: Aaron McKenna; Matthew Hanna; Eric Banks; Andrey Sivachenko; Kristian Cibulskis; Andrew Kernytsky; Kiran Garimella; David Altshuler; Stacey Gabriel; Mark Daly; Mark A DePristo Journal: Genome Res Date: 2010-07-19 Impact factor: 9.043
Authors: Min Ji Jeon; Sung-Min Chun; Deokhoon Kim; Hyemi Kwon; Eun Kyung Jang; Tae Yong Kim; Won Bae Kim; Young Kee Shong; Se Jin Jang; Dong Eun Song; Won Gu Kim Journal: Thyroid Date: 2016-04-13 Impact factor: 6.568
Authors: Min Ji Jeon; Won Gu Kim; Yun Mi Choi; Hyemi Kwon; Yu-Mi Lee; Tae-Yon Sung; Jong Ho Yoon; Ki-Wook Chung; Suck Joon Hong; Tae Yong Kim; Young Kee Shong; Dong Eun Song; Won Bae Kim Journal: Thyroid Date: 2015-12-17 Impact factor: 6.568
Authors: Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz Journal: Genome Biol Date: 2011-04-28 Impact factor: 13.583
Authors: Ryan P Abo; Matthew Ducar; Elizabeth P Garcia; Aaron R Thorner; Vanesa Rojas-Rudilla; Ling Lin; Lynette M Sholl; William C Hahn; Matthew Meyerson; Neal I Lindeman; Paul Van Hummelen; Laura E MacConaill Journal: Nucleic Acids Res Date: 2014-11-26 Impact factor: 16.971
Authors: Sandeep Kumar Parvathareddy; Abdul K Siraj; Kaleem Iqbal; Zeeshan Qadri; Saeeda O Ahmed; Maha Al-Rasheed; Ahmed A AlQatie; Saif S Al-Sobhi; Fouad Al-Dayel; Khawla S Al-Kuraya Journal: Front Endocrinol (Lausanne) Date: 2022-03-11 Impact factor: 5.555